Lyssikatos Joseph P — SEC Form 4 filings
SEC reporting owner CIK 1967150. 34 Form 4 filings on record with FilingPulse; latest filed 2026-02-17.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2024-01-31 to 2026-02-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 52 legs across 31 filings — 466,847 shares, $11,103,927 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 50,000 shares @ $29.13 ($1,456,715) in Enliven Therapeutics, Inc., filed 2026-01-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | 34 | — | 52 legs · 466,847 sh · $11,103,927 | 16 |
Form 4 filings — Lyssikatos Joseph P
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 18,750 @ $0 · Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,000 @ $29.04 | EDGAR |
| 2026-01-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,491 @ $26.37 · Sale (S): 14,509 @ $26.90 | EDGAR |
| 2026-01-12 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 7,500 @ $20.13 · Sale (S): 33,802 @ $24.92 · Sale (S): 41,198 @ $24.90 · Sale (S): 50,000 @ $29.13 | EDGAR |
| 2025-12-23 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,000 @ $16.84 | EDGAR |
| 2025-11-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,008 @ $22.30 · Sale (S): 492 @ $23.09 | EDGAR |
| 2025-10-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,500 @ $22.08 | EDGAR |
| 2025-09-30 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,000 @ $20.25 | EDGAR |
| 2025-09-25 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,500 @ $20.03 | EDGAR |
| 2025-09-23 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,870 @ $19.11 · Sale (S): 2,130 @ $20.02 | EDGAR |
| 2025-08-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,000 @ $19.62 · Sale (S): 7,500 @ $20.01 | EDGAR |
| 2025-07-23 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 11,924 @ $22.26 · Sale (S): 576 @ $22.90 | EDGAR |
| 2025-06-24 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,500 @ $21.40 | EDGAR |
| 2025-06-05 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 7,500 @ $20.03 | EDGAR |
| 2025-05-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,000 @ $16.31 | EDGAR |
| 2025-05-05 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,030 @ $20.07 · Sale (S): 2,470 @ $20.01 | EDGAR |
| 2025-04-23 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,670 @ $16.03 · Sale (S): 330 @ $16.72 | EDGAR |
| 2025-03-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,500 @ $20.61 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 171,000 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 847 @ $30.00 | EDGAR |
| 2024-10-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 13,167 @ $27.96 · Sale (S): 100 @ $28.51 · Sale (S): 34,289 @ $28.12 · Sale (S): 3,589 @ $28.52 | EDGAR |
| 2024-10-08 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 7,522 @ $27.51 · Sale (S): 2,707 @ $27.61 | EDGAR |
| 2024-10-03 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 527 @ $27.54 | EDGAR |
| 2024-09-03 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 11,950 @ $22.48 · Sale (S): 50 @ $23.08 | EDGAR |
| 2024-08-02 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 3,099 @ $27.56 | EDGAR |
| 2024-07-31 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 11,797 @ $26.69 · Sale (S): 203 @ $27.43 | EDGAR |
| 2024-07-03 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 12,000 @ $22.89 | EDGAR |
| 2024-05-31 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 9,877 @ $21.56 · Sale (S): 2,123 @ $22.52 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2024-05-01 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 10,987 @ $17.86 · Sale (S): 1,013 @ $18.48 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 30,000 @ $1.12 · Sale (S): 30,000 @ $25.04 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 2,352 @ $17.72 · Sale (S): 9,577 @ $18.80 · Sale (S): 71 @ $19.36 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 10,195 @ $16.30 · Sale (S): 1,805 @ $17.09 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 12,000 @ $1.12 · Sale (S): 12,000 @ $15.85 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1967150 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →